The Uranium Story just got Bigger thanks to AI – (CSE: $PURR.CN) (OTC: $GLIOF) (NYSE: $URG) (NYSE: $NXE) (TSX: $NXE.TO) (TSXV: $SASK.V) (OTCQB: $SASKF) @PantherMinerals @Ur_Energy @NexGenEnergy_ @athaenergycorp

The Uranium Story just got Bigger thanks to AI – (CSE: $PURR.CN) (OTC: $GLIOF) (NYSE: $URG) (NYSE: $NXE) (TSX: $NXE.TO) (TSXV: $SASK.V) (OTCQB: $SASKF) @PantherMinerals @Ur_Energy @NexGenEnergy_ @athaenergycorp

 

Uranium Miners going Nuclear

 

June 20, 2024 -  Investorideas.com, a global investor news source covering mining and metals stocks releases a snapshot looking at uranium mining and exploration, featuring Panther Minerals Inc.(CSE: PURR) ) (OTC: GLIOF).

 

Panther Minerals Inc. is a mineral exploration company actively involved in the exploration of its North American project portfolio. The acquisition of the Boulder Creek Option reflects the Company's ongoing intention of pursuing advanced, highly quality prospective uranium projects that can be readily worked on and efficiently explored in a timely manner.

 

Uranium prices have had a big year, up over 52%  year to date, with some short term corrections. But the story for uranium miners just got bigger as AI (Artificial Intelligence) is changing the world as we know it and looks to nuclear energy to power its growth.

 

Nuclear energy already had significant tailwinds moving it forward as an energy of choice.  

In December at COP2), 22 countries agreed to triple global nuclear power capacity by 2050 to reach net zero ambitions.

 

Now, as top players like Microsoft fight for dominance in AI, they also are betting on nuclear power to reach their future goals. As AI grows faster than anyone anticipated, it is using up more electricity than our current systems had planned for.

 

Uranium miners and exploration companies see this growth boom as a new Bull Run opportunity.

 

Panther Minerals Inc.(CSE: PURR) (OTC: GLIOF) just issued a corporate update on its Boulder Creek Uranium property, located in the southeastern Seward Peninsula, 160 km east of Nome, Alaska (“Boulder Creek” or the “Property”).

 

This article featuring Panther Minerals Inc. (CSE: PURR) is a paid for service on Investorideas

 

Read this article, featuring PURR in full at https://www.investorideas.com/news/2024/mining/06201Uranium.asp

 

From the news: Panther Minerals has been completing ongoing compilation of all historical data available through previous work conducted by past operators of the Boulder Creek project, Houston Oil & Minerals and Triex Minerals (Full Metal Minerals). With significant historical data available, the Company is looking to continue a full review and analysis of drilling core located on the property and additional core located in Anchorage, Alaska. The data attained will give Panther Minerals a better understanding of the model and formation, as well as the opportunity to utilize its spectrometer to analyze and confirm radiometric readings.

 

From the news: Panther Minerals has submitted drill and work permits for its Boulder Creek property related to a proposal to conduct exploration activities, including diamond drilling, on active federal mining claims that comprise a portion of the Boulder Creek Uranium property, under option by the Company. The Company has engaged Jack DiMarchi, Core Geoscience LLC, to manage the Company’s permitting activities in Alaska. Additional permitting submittals will follow related to activities on the State claims and with regards to the proposed field camp. 

 

Ur-Energy Inc. (NYSE:URG), a uranium mining company operating the Lost Creek in-situ recovery uranium facility in south-central Wyoming is a miner well-known to investors in the sector. They have produced and packaged approximately 2.8 million pounds U3O8 from Lost Creek since the commencement of operations.

 

In May, when the Company announced its quarterly financials, Ur-Energy’s CEO, John Cash said in the news release, "Last week the US Senate, following the House of Representatives action on the same bill, announced the passage by unanimous consent of a Russian Uranium Ban that will commence 90 days after it is signed, subject to certain limited waivers available until January 1, 2028. We are encouraged to see unanimous bipartisan backing of a bill that is likely to result in strong support for western suppliers of nuclear fuel components, including Ur-Energy. We believe we are in the right place at the right time to help fill the uranium supply gap and we will continue to advance production at Lost Creek and Shirley Basin and look for other opportunities to expand our U.S. based production portfolio."

 

In their guidance for 2024 they said, “As uranium prices strengthened, we have received increasing requests for proposals ("RFPs") from utilities and other global fuel buyers. We have responded to the RFPs with prices commensurate with rising market conditions including increased demand for domestically produced uranium. We completed two additional uranium sales agreements during 2024 Q1 and a third agreement subsequent to quarter end. Including the three additional agreements, our contract book now stands at a total of 5.7 million pounds U3O8 with deliveries occurring in 2024 through 2030. Sales prices are anticipated to be profitable on an all-in production cost basis and escalate annually from initial pricing, including some market-based pricing features.”

 

NexGen Energy Ltd. (TSX: NXE) (NYSE: NXE) (ASX: NXG) announced on May 29^th, drilling at Patterson Corridor East intersected mineralization in RK-24-193 over 67.5 metres (m) (383.5 to 451 m) across various intervals including up to 7,500 cps over 1.5 m (Figures 1 to 4, Table 1). RK-24-193 is located 275 m southwest along strike of RK-24-183 (discovery hole) and at approximately the same depth below surface.

 

In addition, assays from RK-24-183 confirm high grade uranium veins across a 20 m interval with several intersections totalling 13.5 m at 0.78% U3O8 including 0.5 m (348.0 to 348.5 m) at 10% U3O8 and another 0.5 m (356.5 to 357 m) at 6.23% U3O8 (Table 2). For reference, the Arrow discovery hole RK-14-21 assayed 5.75 m at 0.37% U3O8, including 0.25 m at 5.77% U3O8.

 

Leigh Curyer, Chief Executive Officer commented: "Our team has assessed the geological similarities between RK-24-183 and RK-24-193 and the upper areas of Arrow, which indicates the high prospectivity of an additional mineralized system 3.5 km east of Arrow. Consequently, the growing potential of this latest discovery will drive the focus of the summer exploration program to determine the potential size and extent of mineralization. Efficient and bold testing of the overall system is the first priority.

 

It is an exciting time at NexGen with the Company recently advancing the Federal Environmental Assessment process for the Rook I Project through the submission of responses to the remaining Information Requests, as well as advancing detailed engineering and exploring a new discovery in parallel."

 

ATHA Energy Corp. (TSX.V:SASK) (OTCQB:SASKF) holder of the largest uranium exploration portfolio in two of the highest-grade uranium districts in the world, announced earlier this month that the Company has commenced Phase I (diamond drilling) of its 2024 Angilak Exploration Program at its 100%-owned Angilak Project in Nunavut. Phase I is comprised of ~10,000 m of diamond drilling targeting the expansion of high-grade uranium mineralization at the Lac 50 Deposit and adjacent mineralized zones.

 

From the news: HIGHLIGHTS:

Angilak Project: The Angilak Project is host to the Lac 50 Uranium Deposit, which is one of the largest high-grade deposits outside of the Athabasca Basin, with a historical mineral resource estimate of 43.3M lbs. at an average grade of 0.69% U3O8.1 Drilling in 2023 by Latitude Uranium (acquired by ATHA) intersected grades of up to 7.54 % U3O8 over 1.6 m.

 

2024 Angilak Exploration Program is part of the Company’s overall 2024 Exploration Program and consists of Phase I (diamond drilling) and Phase II (geophysics & ground geochemistry).

 

As far as what uranium stocks will winners and losers, maybe investors can ask the giant fuelling this boom, ChatGPT, and see what it says.

 

For additional insight into Panther Minerals Inc. (CSE: PURR) listen to the recent Exploring Mining Podcast Interview

 

Listen to the podcast:

https://www.spreaker.com/episode/panther-minerals-inc-the-hunt-for-uranium-in-alaska--60389196

 

Watch on YouTube:

https://youtu.be/XMqJX1aCwu8

 

Research mining stocks at Investorideas.com with our mining stocks directory at Investorideas.com https://www.investorideas.com/Gold_Stocks/Stocks_List.asp 

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: This article featuring Panther Minerals Inc. (CSE: PURR) is a paid for service on Investorideas. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact management and IR of each company directly regarding specific questions.. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas @Exploringmining

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 

 

 

Get more mining stock investor ideas- news, articles, and podcasts and stock directories

 

Cancer Treatment stocks to watch (NASDAQ: $AEMD) (NYSE: $MRK) (NYSE: $BMY) (NYSE: $ABBV) @Merck @bmsnews @abbvie

 

Cancer Treatment stocks to watch (NASDAQ: $AEMD) (NYSE: $MRK) (NYSE: $BMY) (NYSE: $ABBV) @Merck @bmsnews @abbvie

 

What’s next in Treatments for Cancer Patients with Solid Tumors?

June 20, 2024 - Investorideas.com, a go-to investing platform, releases an industry snapshot  looking at the future treatment of solid cancer tumors, featuring Aethlon Medical, Inc. (Nasdaq:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

 

Research released this year predicts, “The solid tumor therapeutics market size will grow from USD 222.71 Billion in 2023 to USD 885.44 Billion in 10 years. Increasing investments of pharmaceutical companies in Research & Development will drive the solid tumor therapeutics market's growth. North America emerged as the largest market for the global Solid Tumor Therapeutics market, accounting for 44% of the total market share globally.”

 

Current drugs available including Merck & Co., Inc.’s (NYSE:MRK) Keytruda® (pembrolizumab) and Bristol Myers Squibb’s (NYSE: BMY) Opdivo® (nivolumab), solve part of the problem but the success rates call for additional solutions.   

 

Aethlon Medical, Inc. (Nasdaq: AEMD) announced this week that, on June, 13, 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for Aethlon’s safety, feasibility and dose-finding clinical trial of the Hemopurifier® in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier® Study). The approval is valid for three years, until June 13, 2027. The trial will be conducted by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital, located in Adelaide, Australia.

 

Currently, only approximately 30% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. Extracellular vesicles (EVs) produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier® has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier® has been shown to reduce the number of exosomes from the plasma of cancer patient samples.

 

This article featuring Aethlon Medical, Inc. is paid for news dissemination

 

Read this article featuring AEMD in full at https://www.investorideas.com/news/2024/biotech/06201Cancer-Treatment-Stocks.asp

 

"The approval from the Human Research Ethics Committee at Central Adelaide Local Health Network marks a significant milestone for Aethlon, as they deemed that our clinical study meets the requirements of the Australia’s National Statement on Ethical Conduct in Human Research,” stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. “We look forward to working closely with Prof. Brown and his staff, and with our Contract Research Organizations, NAMSA and ReSQClinical Research. The next steps include submission to the Therapeutic Goods Administration, the national health regulatory agency of Australia, obtaining approval from the CALHN Research Governance Committee, and conducting a site initiation visit to facilitate patient enrollment. Following this Ethics Board approval, we plan to submit to the Ethics Committees at two additional sites in Australia and one in India.” 

 

The primary endpoint of the approximate 18-patient, safety, feasibility and dose-finding trial is safety. The trial will monitorany adverse events and clinically significant changes in lab tests of Hemopurifier® treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the therapy will be eligible to enter the Hemopurifier® period of the study where sequential cohorts will receive 1, 2 or 3 Hemopurifier® treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier® treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body’s own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies.

 

In May, Bristol Myers Squibb (NYSE:BMY) announced that the US Food and Drug Administration (USFDA) has reassigned the previously announced Prescription Drug User Fee Act (PDUFA) goal date of the Biologics License Application (BLA) for the subcutaneous formulation of Opdivo® (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) (herein referred to as “subcutaneous nivolumab”) across all previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo® plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib. The updated goal date is December 29, 2024.

 

From news: The application is based on results from CheckMate-67T, the first Phase 3 trial of the subcutaneous formulation of nivolumab to evaluate and demonstrate non-inferior pharmacokinetics, efficacy and consistent safety vs. its intravenous formulation. If approved, subcutaneous nivolumab has the potential to be the first and only subcutaneously administered PD-1 inhibitor.

 

From news: CheckMate-67T is a Phase 3 randomized, open-label trial evaluating subcutaneous administration of Opdivo® co-formulated with Halozyme’s proprietary recombinant human hyaluronidase, rHuPH20, or subcutaneous nivolumab (nivolumab and hyaluronidase) compared to intravenous Opdivo, in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy. This trial presents an opportunity to potentially bring a subcutaneous formulation of Opdivo® to patients. A total of 495 patients were randomized to either subcutaneous nivolumab or intravenous Opdivo®. The co-primary endpoints of the trial are time-averaged serum concentration over 28 days (Cavgd28) and trough serum concentration at steady-state (Cminss) of subcutaneous nivolumab vs. intravenous Opdivo®. Objective response rate (ORR) is a key secondary endpoint.

 

According to Merck & Co., Inc. (NYSE:MRK), “KEYTRUDA is not chemotherapy or radiation therapy-it is an immunotherapy and it works with your immune system to help fight cancer. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.”

 

Looking at key developments in the solid tumor market, BrainyInsights reported that In November 2023, AbbVie (NYSE:ABBV) acquired ImmunoGen. The main objective behind this acquisition was to build and expand a strong portfolio base for the Solid Tumor Therapeutics Market. This acquisition will further boost AbbVie’s entry into the commercial market for ovarian cancer.

 

In May, AbbVie showcased its “Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform.”

 

From the news: "Building upon our strong commitment to patients and existing leadership in hematological malignancies, we are rapidly advancing a differentiated pipeline in solid tumors," said Daejin Abidoye, M.D., Vice President, Head of Solid Tumors, Oncology Development, AbbVie. "Our ADC platform allows us to utilize selected biomarkers such as c-Met and SEZ6 to induce targeted cancer cell death by delivering potent anti-cancer agents. The data we are presenting at ASCO demonstrate the clinical potential of this approach across a wide range of difficult-to-treat tumors."

 

From the news: Data from the dose-escalation and colorectal cancer (CRC) dose-expansion cohort of an ongoing first-in-human Phase 1 study (NCT05029882) of ABBV-400, a potential best-in-class c-Met directed ADC, will be presented in an oral presentation. The preliminary data show that among 122 heavily pre-treated advanced CRC patients, promising antitumor activity was observed at 2.4 and 3.0 mg/kg doses administered once every 3 weeks, with confirmed objective response rate (ORR) of 18% (n=40) and 24% (n=41) respectively in those groups. In patients with higher c-Met expression, ORR was enriched to >35% at doses ≥2.4 mg/kg. The most common Gr≥3 treatment-emergent adverse events (TEAEs) were anemia (35%), neutropenia (7%) and febrile neutropenia (6%). TEAEs leading to discontinuation occurred in 25 (20.5%) patients. Additional data will be presented at the meeting.

 

From the news: ABBV-400 is also being evaluated in a Phase 1b basket study (NCT06084481) in advanced solid tumors as a monotherapy and a Phase 2 study (NCT06107413) in second line metastatic CRC in combination with fluorouracil, folinic acid, and bevacizumab.

 

From their Solid Tumor market report, BrainyInsights also says, A huge chunk of pharmaceutical companies continue to make significant contributions to the development of experimental drugs and technologies. The pharmaceutical sector, for instance, is significantly invested in research and development. Pharmaceutical firms invest in future research to bring high-quality, pharmaceuticals to the marketplace. Major pharma firms are boosting their R&D efficiency by investing heavily in R&D, to ensure long returns on investments, as well as by collaborating with R&D centres worldwide. for instance: According to Statista, Roche is expected to be the world’s largest company which is investing heavily in R&D, that is, USD 14 Billion followed by Johnson & Johnson (USD 12.2 Billion), Merck & Co (USD 11.4 Billion), Pfizer (USD 10.5 Billion) and Novartis (USD 10 Billion), by the year 2026.

 

Aethlon Medical, Inc. (Nasdaq: AEMD) says it initiated its tumor-derived exosome research at a time when the medical community believed exosomes were merely cellular debris with no biological function. Today, a therapeutic to address tumor-derived exosomes represents a significant unmet need in cancer care. Aethlon has demonstrated that the affinity mechanism of the Hemopurifier® can capture tumor-derived exosomes and exosomal particles underlying several forms of cancer, including breast, ovarian and metastatic melanoma.

 

Research biotech and medical device/ tech stocks at Investorideas.com

https://www.investorideas.com/BIS/Stock_List.asp

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: This news article featuring AEMD is a paid for news release on Investorideas.com. Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

Rare Earth Breaking News - Defense Metals (TSX-V: $DEFN.V) (OTCQB: $DFMTF) Appoints Guy de Selliers as Chairman of the Board; @defensemetals

 

Vancouver, British Columbia - June 20, 2024 (Investorideas.com Newswire) Defense Metals Corp. ("Defense Metals" or the "Company") (TSX-V:DEFN / OTCQB:DFMTF/ FSE: 35D) is pleased to announce the appointment of Guy de Selliers as Chairman of the Board of Directors of the Company. 

 

Mr. de Selliers, a director of Defense Metals, is a highly experienced professional with an illustrious career and will bring over four decades of expertise and vision as the Chairman of the Boad of Defense Metals. 

 

Throughout his career, Mr. de Selliers has been a board member of numerous influential organizations including Solvay Group, Ageas Group, AG Insurance Belgium, Ivanhoe Mining, Advanced Metallurgical Group AMG, Norilsk Nickel, Wimm Bill Dann. He currently sits on the boards of I Pulse, a private high-tech company in France, The Cranemere Group Ltd., a privately held financial holding company in the UK, and Radix, a think-tank for the Radical Center (UK). He has been Chairman of the Board in a number of occasions most recently of AG Insurance, the largest Belgian Insurance company. He combines thus very strong corporate governance credential with extensive experience in mining, industry and finance. 

 

This news is paid advertisement/ news disseminated on behalf of/ issued on behalf of Defense Metals Corp.

 

Read this news, featuring DEFN in full at https://www.investorideas.com/news/2024/06201DEFN-Guy-de-Selliers.asp

 

About Defense Metals Corp. and its Wicheeda Rare Earth Element Project

Defense Metals Corp. is focused on the development of its 100% owned, 8,301-hectare (~20,534-acre) Wicheeda REE Project that is located on the traditional territory of the McLeod Lake Indian Band in British Columbia, Canada.

 

The Wicheeda REE Project, approximately 80 kilometres (~50 miles) northeast of the city of Prince George, is readily accessible by a paved highway and all-weather gravel roads and is close to infrastructure, including hydro power transmission lines and gas pipelines. The nearby Canadian National Railway and major highways allow easy access to the port facilities at Prince Rupert, the closest major North American port to Asia.

 

Defense Metals is a proud member of Discovery Group. For more information please visit:

www.discoverygroup.ca.

 

For further information, please visit www.defensemetals.com or contact:

 

Alex Heath

Vice President, Corporate Development  

Tel: 1 604-354-2491

Email: alex@defensemetals.com

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

 

Cautionary Statement Regarding “Forward-Looking” Information

 

This news release contains “forward–looking information or statements” within the meaning of applicable securities laws, which may include, without limitation, statements relating to advancing the Wicheeda REE Project, the expectations and plans for the Wicheeda REE Project, the technical, financial and business prospects of the Company, its project, goals and other matters. All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the price of rare earth elements, the anticipated costs and expenditures, the ability to achieve its goals, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms. Such forward-looking information reflects the Company's views with respect to future events and is subject to risks, uncertainties and assumptions, including the risks and uncertainties relating to the interpretation of exploration and metallurgical results, risks related to the inherent uncertainty of exploration and development and cost estimates, the potential for unexpected costs and expenses and those other risks filed under the Company’s profile on SEDAR+ (www.sedarplus.ca). While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks. Factors that could cause actual results to differ materially from those in forward looking statements include, but are not limited to, continued availability of capital and financing and general economic, market or business conditions, adverse weather and climate conditions, failure to maintain or obtain all necessary government permits, approvals and authorizations, failure to maintain or obtain community acceptance (including First Nations), risks relating to unanticipated operational difficulties (including failure of equipment or processes to operate in accordance with specifications or expectations, cost escalation, unavailability of personnel, materials and equipment, government action or delays in the receipt of government approvals, industrial disturbances or other job action, and unanticipated events related to health, safety and environmental matters), risks relating to inaccurate geological, metallurgical, engineering and pricing assumptions, decrease in the price of rare earth elements, the impact of viruses and diseases on the Company’s ability to operate, restriction on labour and international travel and supply chains, loss of key employees, consultants, officers or directors, increase in costs, delayed results, litigation, and failure of counterparties to perform their contractual obligations. The Company does not undertake to update forward–looking statements or forward–looking information, except as required by law.

 

Defense Metals Corp. (TSX-V:DEFN /OTCQB:DFMTF) is a featured mining stock on Investorideas.com

 

More info on DEFN.V at Investorideas.com Visit: https://www.investorideas.com/CO/DEFN/

 

Get News Alerts on Defense Metals Corp DEFN

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure   this  DEFN news is a paid  featured annual mining stock  on investorideas.com – learn more about costs and services https://www.investorideas.com/News-Upload/  More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp  Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com                                           

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Renewable Energy Stocks: investing ideas in renewable energy stocks

Like Renewable Energy Stocks? View our Renewable Energy Stocks Directory

Get News Alerts on Renewable Energy Stocks

 

Mining Sector Stocks- investing ideas in mining stocks

Like Mining Stocks? View our Mining Stocks Directory 

 Get News Alerts on Mining Stocks

 

Breaking Uranium Stock News - Pegasus (TSXV: $PEGA.V) (OTC PINK: $SLTFF) Shareholders Approve All Matters at the 2024 AGM; @pegasusresinc

Breaking Uranium Stock News - Pegasus (TSXV: $PEGA.V) (OTC PINK: $SLTFF) Shareholders Approve All Matters at the 2024 AGM; @pegasusresinc

 

Vancouver, Canada - June 19, 2024 (Investorideas.com Newswire) Pegasus Resources Inc. (TSX-V:PEGA) (OTCPK:SLTFF) (Frankfurt:0QS0) (the "Company" or "Pegasus") is pleased to announce that all resolutions were passed at the Annual General Meeting held on June 18, 2024.

 

The four nominees to be elected as directors listed in the Company's information circular dated May 14, 2024, were elected as directors of the Company for the ensuing year and the number of directors was fixed at four. Christian Timmins, Dave Bissoondatt, Noah Komavli and Derrick Strickland were all elected as directors of the Company by a majority of the votes cast by shareholders present or represented by proxy at the meeting.

 

Crowe MacKay LLP of Vancouver, British Columbia will remain as the auditor of the Company for the ensuing year until the next annual general meeting at a remuneration to be fixed by the directors. The Company's 10% rolling stock option plan also received the required shareholder approval.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of Pegasus Resources Inc.

 

Read this news, featuring PEGA in full at https://www.investorideas.com/news/2024/06191PEGA-Shareholders-Approve-2024-AGM.asp

 

About Pegasus Resources Inc.

Pegasus Resources Inc. is a diversified Junior Canadian Mineral Exploration Company with a focus on uranium, gold and base metal properties in North America. The Company is also actively pursuing the right opportunity in other resources to enhance shareholder value. For additional information please visit the Company at www.pegasusresourcesinc.com.

 

On Behalf of the Board of Directors:

 

Christian Timmins

President, CEO and Director
Pegasus Resources Inc.
700 - 838 West Hastings Street
Vancouver, BC V6C 0A6
PH: 1-403-597-3410

X: https://twitter.com/MrChris_Timmins
X: https://twitter.com/pegasusresinc
E: info@pegasusresourcesinc.com

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE: Pegasus Resources Inc.

 

Pegasus Resources Inc. (TSX-V:PEGA) (OTCPK:SLTFF) (Frankfurt:0QS0) is a featured mining stock on Investorideas.com

 

More info on PEGA at Investorideas.com Visit: https://www.investorideas.com/CO/PEGA/

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact management and IR of each company directly regarding specific questions. Disclosure: Pegasus Resources Inc is a paid for mining client at InvestorIdeas.com. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

Get more mining stock investor ideas- news, articles, and podcasts and stock directories